Investigating the efficacy of baricitinib in new onset type 1 diabetes mellitus (BANDIT)—study protocol for a phase 2, randomized, placebo controlled trial

The JAK1 Selective Inhibitor ABT 317 Blocks Signaling Through Interferon-γ and Common γ Chain Cytokine Receptors to Reverse Autoimmune Diabetes in NOD Mice

(2020) Tingting Ge et al.   Frontiers in Immunology

The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases

(2020) William Damsky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Baricitinib for systemic lupus erythematosus – Authors' reply

(2019) Daniel J Wallace et al.   LANCET

Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis

(2019) Charalampia Papadopoulou et al.   BRAIN

Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

(2019) Anniina T. Virtanen et al.   BIODRUGS

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

(2018) Gina A. Montealegre Sanchez et al.   JOURNAL OF CLINICAL INVESTIGATION

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study

(2018) Emma Guttman-Yassky et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

(2018) Daniel J Wallace et al.   LANCET

Beta cell function in type 1 diabetes determined from clinical and fasting biochemical variables

(2018) John M. Wentworth et al.   DIABETOLOGIA

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

(2018) Josef S. Smolen et al.   JOURNAL OF RHEUMATOLOGY

The emerging safety profile of JAK inhibitors in rheumatic disease

(2017) Kevin L. Winthrop   Nature Reviews Rheumatology

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment

(2017) Roy Fleischmann et al.   Arthritis & Rheumatology

Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response

(2017) Matthew Clark et al.   Frontiers in Immunology

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

(2016) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

A model-based approach to sample size estimation in recent onset type 1 diabetes

(2016) Brian N. Bundy et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-analysis of shared genetic architecture across ten pediatric autoimmune diseases

(2015) Yun R Li et al.   NATURE MEDICINE

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

(2015) Ali Jabbari et al.   EBioMedicine

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate

(2014) Edward C Keystone et al.   ANNALS OF THE RHEUMATIC DISEASES

Proinflammatory cytokines contribute to development and function of regulatory T cells in type 1 diabetes

(2012) Helen E. Thomas et al.   Annals of the New York Academy of Sciences

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data

(2012) C. J. Greenbaum et al.   DIABETES